Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.
Find links to advocacy organisations, information on testing and research resources, and primary hyperoxaluria type 1 (PH1) educational materials below.
Alnylam Pharmaceuticals sponsors third-party genetic testing and counselling for individuals who may carry gene mutations known to be associated with PH1.
See how genetic testing plays an important role in a PH1 diagnosis.1,3
PH1-INTR-00024 | January 2025
ThinkPH1 is a trademark of Alnylam Pharmaceuticals, Inc.
©2025 Developed and produced by Alnylam Switzerland GmbH. All rights reserved.
PH1-INTR-00025
January 2025
Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.
By accessing the website, you confirm to be a Healthcare Professional from Europe, Middle East, or Africa:
If you are not a Healthcare Professional, please access the LivingwithPH1.eu website here.